[Pubmed] Multiple Autoimmune Complications After a Single Dose of Pembrolizumab
Posté : 10 avr. 2023 12:00
Cureus. 2023 Mar 7;15(3):e35871. doi: 10.7759/cureus.35871. eCollection 2023 Mar.
ABSTRACT
Pembrolizumab, a monoclonal antibody that inhibits programmed cell death protein-1 (PD-1), is an important treatment for various malignancies. Unfortunately, it has also been associated with a wide array of immune-related adverse events. We present a unique case of a patient who received a single dose of pembrolizumab and subsequently developed multiple immune-mediated complications, including dermatitis, hepatitis, myositis, myocarditis, and myasthenia gravis.
PMID:37033516 | PMC:PMC10079282 | DOI:10.7759/cureus.35871
Source: https://pubmed.ncbi.nlm.nih.gov/3703351 ... t6+86293ac